Table 2 |
||||||
|
Clinical and parasitological therapeutic outcome |
||||||
|
AL (Ipinda site) |
AS+AQ (Mlimba site) |
|||||
|
|
||||||
|
End points |
Before PCR corrections |
After PCR corrections |
Before PCR corrections |
After PCR corrections |
||
|
|
|
|||||
|
With unresolved PCR |
Without unresolved PCR |
With unresolved PCR |
Without unresolved PCR |
|||
|
|
||||||
|
ETF |
0 (0.00) |
0 (0.00) |
0 (0.00) |
1 (1.5) |
1 (1.6) |
1 (2.0) |
|
LCF |
1 (1.0) |
1 (1.1) |
0 (0.00) |
4 (6.1) |
3 (4.8) |
2 (4.2) |
|
LPF |
11 (12.0) |
5 (5.6) |
0 (0.00) |
19 (29.2) |
4 (6.5) |
0 (0.00) |
|
ACPR |
80 (87.0) |
83 (93.3) |
86 (100) |
41 (63.2) |
54 (87.1) |
45 (93.8) |
|
|
||||||
|
Total |
92 |
89 |
86 |
65 |
62 |
48 |
|
|
||||||
|
Kabanywanyi et al. Malaria Journal 2007 6:146 doi:10.1186/1475-2875-6-146 |
||||||